ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02518685 |
Recruitment Status :
Completed
First Posted : August 10, 2015
Results First Posted : July 17, 2019
Last Update Posted : July 17, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Device: TransPyloric Shuttle Device: Sham procedure Behavioral: Lifestyle Counseling | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 302 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study |
Study Start Date : | September 2015 |
Actual Primary Completion Date : | December 2017 |
Actual Study Completion Date : | March 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: TransPyloric Shuttle (TPS)
TransPyloric Shuttle plus Lifestyle Counseling
|
Device: TransPyloric Shuttle
Other Name: TPS Behavioral: Lifestyle Counseling The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies. |
Sham Comparator: Control
Sham procedure plus Lifestyle Counseling
|
Device: Sham procedure Behavioral: Lifestyle Counseling The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies. |
- Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group [ Time Frame: 12 Months ]The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline
- Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL [ Time Frame: 12 months ]The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50%
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female subjects between the ages of 22 to 60
- A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to 34.9 kg/m2 are required to have one or more obesity-related comorbidities
- History of obesity for at least 2 years, with history of failure of medically or commercially supervised weight loss program
- < 5% change in body weight for at least 3 months
- Negative pregnancy test, agree to be on birth control for the duration of participation
- Informed consent
- Willing and able to comply with study procedures
Exclusion Criteria:
- Pregnancy or nursing
- Hormonal or genetic cause for obesity
- Prior history of any GI surgery or endoscopic intervention
- Chronic use of medications likely to contribute to weight gain or prevent weight loss
- Gastric or duodenal ulcers
- Positive for H. pylori
- History of severe dyspepsia
- GI tract motility disorders
- History of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal hypertension, cirrhosis, and/or varices
- Diabetes treated with insulin
- HbA1c >7.5%
- Uncontrolled thyroid and adrenal gland disease or uncontrolled hypertension
- History of certain cardiac events
- Localized or systemic infection
- Anemia
- History of asthma likely to require systemic steroid therapy
- Autoimmune connective tissue disorders or immunocompromised
- History of malignancy except non-melanoma skin cancer
- Continuous use of ulcerogenic medication
- On anticoagulation or antiplatelet therapy
- Use of weight-loss medication
- In other weight-loss program
- Unable to take proton pump inhibitor
- Abnormal laboratory values or EKG
- Inability to walk at least 0.8 kilometers per day
- Planned surgical procedure that can impact the conduct of the study
- Known allergy to any component materials in the TPSS
- Smoker or user of nicotine product
- Substance abuse
- Severe, uncontrolled psychiatric illness
- Recent inpatient psychiatric treatment
- Moderate depression
- Bulimia nervosa or binge eating disorder
- Participation in another clinical study
- Employee or family member of Sponsor or study staff
- Have any endoscopic exclusion criteria
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02518685
United States, Arizona | |
HonorHealth Bariatric Center | |
Scottsdale, Arizona, United States, 85258 | |
United States, California | |
University of California San Diego | |
San Diego, California, United States, 92103 | |
United States, Florida | |
University of Miami | |
Miami, Florida, United States, 33166 | |
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 | |
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 | |
United States, New York | |
Stony Brook Medicine | |
Stony Brook, New York, United States, 11794 | |
United States, Tennessee | |
MidSouth Bariatrics | |
Memphis, Tennessee, United States, 38120 | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States, 37232 | |
United States, Texas | |
Baylor University Medical Center | |
Dallas, Texas, United States, 75246 |
Principal Investigator: | Richard I Rothstein, MD | Dartmouth Geisel School of Medicine |
Documents provided by BaroNova, Inc.:
Responsible Party: | BaroNova, Inc. |
ClinicalTrials.gov Identifier: | NCT02518685 |
Other Study ID Numbers: |
DTC006 |
First Posted: | August 10, 2015 Key Record Dates |
Results First Posted: | July 17, 2019 |
Last Update Posted: | July 17, 2019 |
Last Verified: | April 2019 |
Obesity Weight loss Device Non-surgical |
Endoscopic TransPyloric Shuttle TPS |
Obesity Overweight Overnutrition Nutrition Disorders Body Weight |